Not provided
Not provided
Not provided
Not provided
difficulty in recruiting
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| University Hospital, Angers | OTHER_GOV |
| Poitiers University Hospital | OTHER |
| Union hospital, Toulouse | UNKNOWN |
| Hospital Alpes Leman, Annemasse |
Not provided
Not provided
Not provided
Not provided
Obesity is a major risk factor for obstructive sleep apnea (OSA). However, OSA is still largely under diagnosed in patients with a high cardiovascular risk. In this population the STOP-BANG questionnaire facilitates OSA screening. Moreover, blood bicarbonate concentration is a simple tool to screen for chronic respiratory disease and if elevated, is a marker of cardiometabolic comorbidities in obese patients. A combination of blood bicarbonate concentration and STOP BANG score could provide a cost-effective method of screening for OSA in obese patients. Such screening could enable earlier management and might significantly reduce the costs of treatment and improve the quality of life of patients at 2 years.
OSA is a frequent condition in the general population (3% of women and 10% of men), but remains largely undiagnosed. Obesity is a risk factor for OSA. Sleep apnea is associated with diurnal and nocturnal symptoms (snoring, somnolence, fatigue), and with increased cardiometabolic morbidity and mortality. Currently, continuous positive airway pressure (CPAP) is the gold-standard treatment for OSA and the cost-effectiveness of this treatment has already been demonstrated. Easy-to-use procedures to identify OSA patients earlier and thus to initiate treatment earlier, need to be developed and validated. The STOP-BANG questionnaire has been designed to facilitate the screening of OSA patients. Moreover, a measure of blood bicarbonate concentration is a simple method for screening for chronic respiratory diseases and a marker of cardiometabolic comorbidities. A combination of blood bicarbonate measurement and STOP-BANG score could permit earlier screening and less expensive care of obese patients. The hypothesize is that such OSA screening in the obese population (bicarbonates + STOPBANG) associated with earlier care (with treatment if necessary) could lead to improvement in quality of life of obese patients at 2 years.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Usual care | No Intervention | Patients in the usual care group will be referred to their general practitioner (GP) / primary care practitioner as usual. | |
| Early care | Active Comparator | A different care pathway will be followed by the patients randomized to this group. They will be referred to a specialist (pneumologist) for OSA diagnosis and treatment if necessary |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Care pathway | Other | Screening for OSA using a combination of bicarbonate assay and STOP-BANG questionnaire and further management by a pneumologist as necessary |
|
| Measure | Description | Time Frame |
|---|---|---|
| 2-year medico-economic impact of the implementation of early care in obese patients with OSA | incremental cost-effectiveness ratio at 24 months calculated from the difference in healthcare costs between the 2 groups (early care vs usual care) adjusted to the difference in the number of quality adjusted life years | 24 months |
| Measure | Description | Time Frame |
|---|---|---|
| Economic impact of the implementation of early care in obese patients with OSA over 3 years on the healthcare costs | The economic impact on healthcare costs from the Health Insurer's perspective will be calculated from the difference in healthcare costs between the two groups (early care vs usual care) | 3 years |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Jean-Louis PEPIN, MD, PhD | Grenoble Alpes University Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| ORIADE | Vizille | France |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D010845 | Obesity Hypoventilation Syndrome |
| D020181 | Sleep Apnea, Obstructive |
| ID | Term |
|---|---|
| D012891 | Sleep Apnea Syndromes |
| D001049 | Apnea |
| D012120 | Respiration Disorders |
| D012140 | Respiratory Tract Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D019091 | Critical Pathways |
| ID | Term |
|---|---|
| D010347 | Patient Care Planning |
| D003191 | Comprehensive Health Care |
| D010346 | Patient Care Management |
| D006298 | Health Services Administration |
Not provided
Not provided
| UNKNOWN |
| Hospital La Louvière, Lille | UNKNOWN |
| Oriade Laboratory, Vizille | UNKNOWN |
| Cerballiance laboratories, Lille | UNKNOWN |
| Oriade laboratory, Annemasse | UNKNOWN |
Open, controlled, randomized clinical trial (cluster randomization)
Not provided
Not provided
Not provided
Not provided
| To evaluate the sensitivity of the screening tool |
The sensitivity will be evaluated by comparison with polysomnography |
| 24 months |
| To evaluate the specificity of the screening tool | The specificity will be evaluated by comparison with polysomnography | 24 months |
| To evaluate the negative Predictive Value | The negative predictive value will be evaluated by comparison with polysomnography | 24 months |
| To evaluate the positive predictive value of the screening tool | The positive predictive value will be evaluated by comparison with polysomnography | 24 months |
| Clinical impact of the early care pathway on blood pressure at 12 months | Blood pressure at home | 12 months |
| Clinical impact of the early care pathway on blood pressure at 24 months | Blood pressure at home | 24 months |
| Clinical impact of the early care pathway on quality of life at 12 months | The EQ-5D-5L health status questionnaire, This scale is numbered from 0 to 100. 100 means the best health status. 0 means the worst health status. | 12 months |
| Clinical impact of the early care pathway on quality of life at 24 months | The EQ-5D-5L health status questionnaire, This scale is numbered from 0 to 100. 100 means the best health status. 0 means the worst health status. | 24 months |
| Clinical impact of the early care pathway (early care) on quality of life at 12 months | Stroke and Aphasia Quality of Life Scale (SAQOL), This questionnaire is intended to study the relationship between sleep and the quality of life. This scale is numbered from 0 to 4. higher values represent a worse outcome | 12 months |
| Clinical impact of the early care pathway (early care) on quality of life at 24 months | Stroke and Aphasia Quality of Life Scale (SAQOL), This questionnaire is intended to study the relationship between sleep and the quality of life. This scale is numbered from 0 to 4. higher values represent a worse outcome | 24 months |
| Clinical impact of the early care pathway on pharmacological treatments at 12 months | number of pharmacological treatments | 12 months |
| Clinical impact of the early care pathway on pharmacological treatments at 24 months | number of pharmacological treatments | 24 months |
| Impact on laboratory test results (troponin) at 12 months | troponin | 12 months |
| Impact on laboratory test results (troponin) at 24 months | troponin | 24 months |
| Impact on laboratory test results (NT-proBNP) at 12 months | NT-proBNP | 12 months |
| Impact on laboratory test results (NT-proBNP) at 24 months | NT-proBNP | 24 months |
| Impact on laboratory test results on cholesterol at 12 months | cholesterol | 12 months |
| Impact on laboratory test results on cholesterol at 24 months | cholesterol | 24 months |
| Impact on laboratory test results on triglycerides at 12 months | triglycerides | 12 months |
| Impact on laboratory test results on triglycerides at 24 months | triglycerides | 24 months |
| Impact on laboratory test results on glycaemia at 12 months | glycaemia | 12 months |
| Impact on laboratory test results on glycaemia at 24 months | glycaemia | 24 months |
| Impact on laboratory test results on Homeostasis model assessment (HOMA)-index at 12 months | Homeostasis model assessment (HOMA)-index | 12 months |
| Impact on laboratory test results on Homeostasis model assessment (HOMA)-index at 24 months | Homeostasis model assessment (HOMA)-index | 24 months |
| Impact on laboratory test results on hepatic transaminases at 12 months | transaminases (ASAT, ALAT) | 12 months |
| Impact on laboratory test results on hepatic transaminases at 24 months | transaminases (ASAT, ALAT) | 24 months |
| Impact on laboratory test results on creatinine at 12 months | creatinine | 12 months |
| Impact on laboratory test results on creatinine at 24 months | creatinine | 24 months |
| Impact on laboratory test results on C-Reactive Protein (CRP) at 12 months | C-Reactive Protein (CRP) | 12 months |
| Impact on laboratory test results on C-Reactive Protein (CRP) at 24 months | C-Reactive Protein (CRP) | 24 months |
| Impact on laboratory test results on alpha2-macroglobulin at 12 months | alpha2-macroglobulin | 12 months |
| Impact on laboratory test results on alpha2-macroglobulin at 24 months | alpha2-macroglobulin | 24 months |
| D007040 |
| Hypoventilation |
| D012131 | Respiratory Insufficiency |
| D020919 | Sleep Disorders, Intrinsic |
| D020920 | Dyssomnias |
| D012893 | Sleep Wake Disorders |
| D009422 | Nervous System Diseases |
| D009765 | Obesity |
| D050177 | Overweight |
| D044343 | Overnutrition |
| D009748 | Nutrition Disorders |
| D009750 | Nutritional and Metabolic Diseases |